WO2009139891A3 - Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof - Google Patents

Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof Download PDF

Info

Publication number
WO2009139891A3
WO2009139891A3 PCT/US2009/003016 US2009003016W WO2009139891A3 WO 2009139891 A3 WO2009139891 A3 WO 2009139891A3 US 2009003016 W US2009003016 W US 2009003016W WO 2009139891 A3 WO2009139891 A3 WO 2009139891A3
Authority
WO
WIPO (PCT)
Prior art keywords
alk1
bmp9
bmp10
antagonists
ligands
Prior art date
Application number
PCT/US2009/003016
Other languages
French (fr)
Other versions
WO2009139891A2 (en
Inventor
Jasbir Seehra
John Knopf
Robert S. Pearsall
Asya Grinberg
Ravindra Kumar
Original Assignee
Acceleron Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma, Inc. filed Critical Acceleron Pharma, Inc.
Priority to EP09746978A priority Critical patent/EP2291401A2/en
Priority to CA2724525A priority patent/CA2724525A1/en
Publication of WO2009139891A2 publication Critical patent/WO2009139891A2/en
Publication of WO2009139891A3 publication Critical patent/WO2009139891A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
PCT/US2009/003016 2008-05-15 2009-05-15 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof WO2009139891A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09746978A EP2291401A2 (en) 2008-05-15 2009-05-15 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
CA2724525A CA2724525A1 (en) 2008-05-15 2009-05-15 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5364408P 2008-05-15 2008-05-15
US61/053,644 2008-05-15

Publications (2)

Publication Number Publication Date
WO2009139891A2 WO2009139891A2 (en) 2009-11-19
WO2009139891A3 true WO2009139891A3 (en) 2010-02-18

Family

ID=40886532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/003016 WO2009139891A2 (en) 2008-05-15 2009-05-15 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof

Country Status (3)

Country Link
EP (1) EP2291401A2 (en)
CA (1) CA2724525A1 (en)
WO (1) WO2009139891A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
MX2009004718A (en) 2006-11-02 2009-06-19 Acceleron Pharma Inc Alk1 receptor and ligand antagonists and uses thereof.
WO2009134428A2 (en) * 2008-05-02 2009-11-05 Acceleron Pharma, Inc. Methods and compositions for modulating angiogenesis and pericyte composition
US20160228509A9 (en) * 2009-05-08 2016-08-11 Novartis Ag Diagnostic BioMarkers for Fibrotic Disorders
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
US10047155B2 (en) 2015-06-05 2018-08-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113590A2 (en) * 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
US20070065444A1 (en) * 2005-09-07 2007-03-22 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2008057461A2 (en) * 2006-11-02 2008-05-15 Acceleron Pharma, Inc. Alk1 receptor and ligand antagonists and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897581B2 (en) * 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
CA2703099A1 (en) * 2007-11-09 2009-05-14 Genentech, Inc. Activin receptor-like kinase-i compositions and methods of use
WO2009134428A2 (en) * 2008-05-02 2009-11-05 Acceleron Pharma, Inc. Methods and compositions for modulating angiogenesis and pericyte composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113590A2 (en) * 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
US20070065444A1 (en) * 2005-09-07 2007-03-22 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2008057461A2 (en) * 2006-11-02 2008-05-15 Acceleron Pharma, Inc. Alk1 receptor and ligand antagonists and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID LAURENT ET AL: "Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 109, no. 5, 1 March 2007 (2007-03-01), pages 1953 - 1961, XP002490787, ISSN: 0006-4971, [retrieved on 20061026] *
SCHARPFENECKER MARION ET AL: "BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 120, no. 6, 1 March 2007 (2007-03-01), pages 964 - 972, XP002490785, ISSN: 0021-9533 *
See also references of EP2291401A2 *
UNGEFROREN HENDRIK ET AL: "Antitumor activity of ALK1 in pancreatic carcinoma cells", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 120, no. 8, 1 April 2007 (2007-04-01), pages 1641 - 1651, XP002490786, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
CA2724525A1 (en) 2009-11-19
EP2291401A2 (en) 2011-03-09
WO2009139891A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2008057461A3 (en) Alk1 receptor and ligand antagonists and uses thereof
WO2009134428A3 (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
WO2009139891A3 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
WO2012003418A3 (en) Functionally selective ligands of dopamine d2 receptors
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
MY155621A (en) Axl antibodies
WO2009098448A8 (en) Compounds
MX2011013172A (en) Methods for increasing thermogenic adipocytes.
PH12015501515A1 (en) Anti-cmet antibody
ME02330B (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspiro [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
WO2008155558A3 (en) Microspheres
WO2009142732A3 (en) Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
WO2009115572A3 (en) Novel heterocyclic compounds and uses therof
EP2551270A3 (en) Pyrazolopyrmidine derivatives for use as pi3 kinase antagonists
MX2011011825A (en) Humanized axl antibodies.
PL2094690T3 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
WO2014096440A3 (en) Albumin composition for preventing and/or reducing formation of peptide fibrils
WO2011143457A3 (en) Compositions and methods for treating or preventing atrial fibrillation
PL2013236T3 (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
WO2007005780A3 (en) Compositions and methods for treating gastrointestinal hypomotility and associated disorders
WO2010120695A3 (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
WO2009043355A3 (en) SYSTEMIC PRO-HEMOSTATIC EFFECT OF SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09746978

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 1011870

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20090515

WWE Wipo information: entry into national phase

Ref document number: 2724525

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009746978

Country of ref document: EP